The drug maker said the audit of its API manufacturing plant at Miryalaguda in Telangana, by the US FDA, has been completed.

Phase II studies for DFA-02 have been successfully completed and the product will now be transitioning to Phase III registration studies.

The drug is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery.

If there were hopes that the current CPM leadership would take inspiration to recruit young talent, the just-concluded 20th party cong disp...